160 related articles for article (PubMed ID: 21804830)
21. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy.
Haeberli G; Brönnimann M; Hunziker T; Müller U
Clin Exp Allergy; 2003 Sep; 33(9):1216-20. PubMed ID: 12956741
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
23. Simplification of intradermal skin testing in Hymenoptera venom allergic children.
Cichocka-Jarosz E; Stobiecki M; Brzyski P; Rogatko I; Nittner-Marszalska M; Sztefko K; Czarnobilska E; Lis G; Nowak-Węgrzyn A
Ann Allergy Asthma Immunol; 2017 Mar; 118(3):326-332. PubMed ID: 27986410
[TBL] [Abstract][Full Text] [Related]
24. Venom immunotherapy: clinical efficacy, safety and contraindications.
Kosnik M; Korosec P
Expert Rev Clin Immunol; 2015; 11(8):877-84. PubMed ID: 26018865
[TBL] [Abstract][Full Text] [Related]
25. Hymenoptera ultra-rush venom immunotherapy (210 min): a safety study and risk factors.
Birnbaum J; Ramadour M; Magnan A; Vervloet D
Clin Exp Allergy; 2003 Jan; 33(1):58-64. PubMed ID: 12534550
[TBL] [Abstract][Full Text] [Related]
26. Safety of rush insect venom immunotherapy. The results of a retrospective study in 178 patients.
Wenzel J; Meissner-Kraemer M; Bauer R; Bieber T; Gerdsen R
Allergy; 2003 Nov; 58(11):1176-9. PubMed ID: 14616130
[TBL] [Abstract][Full Text] [Related]
27. Early effect of ultrarush venom immunotherapy on the IgG antibody response.
Michils A; Baldassarre S; Ledent C; Mairesse M; Gossart B; Duchateau J
Allergy; 2000 May; 55(5):455-62. PubMed ID: 10843426
[TBL] [Abstract][Full Text] [Related]
28. Agreement of skin test with IL-4 production and CD40L expression by T cells upon immunotherapy of subjects with systemic reactions to Hymenoptera stings.
Urra JM; Cabrera CM; Alfaya T; Feo-Brito F
Mol Immunol; 2016 Feb; 70():134-9. PubMed ID: 26774053
[TBL] [Abstract][Full Text] [Related]
29. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses.
Ruëff F; Wenderoth A; Przybilla B
J Allergy Clin Immunol; 2001 Dec; 108(6):1027-32. PubMed ID: 11742283
[TBL] [Abstract][Full Text] [Related]
30. The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice.
Engin A; Oktelik FB; Gelincik A; Sin A; Sin BA; Dursun BA; Beyaz S; Gorgulu B; Cetin E; Deniz G
Allergy Asthma Proc; 2021 Jul; 42(4):350-356. PubMed ID: 34187627
[No Abstract] [Full Text] [Related]
31. Utility of laboratory testing for the diagnosis of Hymenoptera venom allergy.
Vachová M; Panzner P; Malkusová I; Hanzlíková J; Vlas T
Allergy Asthma Proc; 2016 May; 37(3):248-55. PubMed ID: 27178893
[TBL] [Abstract][Full Text] [Related]
32. Venom immunotherapy for preventing allergic reactions to insect stings.
Boyle RJ; Elremeli M; Hockenhull J; Cherry MG; Bulsara MK; Daniels M; Oude Elberink JN
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD008838. PubMed ID: 23076950
[TBL] [Abstract][Full Text] [Related]
33. The incidence and nature of adverse reactions to injection immunotherapy in bee and wasp venom allergy.
Youlten LJ; Atkinson BA; Lee TH
Clin Exp Allergy; 1995 Feb; 25(2):159-65. PubMed ID: 7750008
[TBL] [Abstract][Full Text] [Related]
34. The adhesion molecule ICAM-1 is overexpressed in patients with Hymenoptera venom allergy and decreases after ultrarush venom immunotherapy.
Patella V; Incorvaia C; Ricciardi L; Florio G; Saija A; Frati F; Gangemi S
J Biol Regul Homeost Agents; 2011; 25(3):465-8. PubMed ID: 22023772
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent sting recurrence and outcome in immunotherapy-treated children with anaphylaxis to Hymenoptera venom.
Stritzke AI; Eng PA
Clin Exp Allergy; 2013 Aug; 43(8):950-5. PubMed ID: 23889248
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of venom immunotherapy: a real life study.
Kołaczek A; Skorupa D; Antczak-Marczak M; Kuna P; Kupczyk M
Postepy Dermatol Alergol; 2017 Apr; 34(2):159-167. PubMed ID: 28507496
[TBL] [Abstract][Full Text] [Related]
37. Effects of venom immunotherapy on serum level of CCL5/RANTES in patients with Hymenoptera venom allergy.
Gawlik R; Glück J; Jawor B; Rogala B
Immunopharmacol Immunotoxicol; 2015; 37(4):375-9. PubMed ID: 26181651
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of rush immunotherapy in patients with Hymenoptera allergy in Japan.
Hirata H; Asakura T; Arima M; Cheng G; Honda K; Fukushima F; Yamaguchi B; Yoshida N; Fukuda T
Asian Pac J Allergy Immunol; 2003 Jun; 21(2):89-94. PubMed ID: 14629126
[TBL] [Abstract][Full Text] [Related]
39. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial.
Reimers A; Hari Y; Müller U
Allergy; 2000 May; 55(5):484-8. PubMed ID: 10843430
[TBL] [Abstract][Full Text] [Related]
40. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
